Sarcomas

Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.

Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.

Michael C. Heinrich, MD, discusses the recent approval of avapritinib for advanced PDGFRA exon 18–mutated gastrointestinal stromal tumor.

Multiple immune-infiltrate features in the immune-genomic landscape of osteosarcoma, such as poor tumor infiltration by immune cells, low T-cell activity, a lack of immune-stimulating neoantigens, and immune-suppressing pathways, contribute to the limited clinical activity associated with checkpoint inhibitors in this disease, according to results of a study published in Nature Communications.

Alexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.

C. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.

Alexander Leandros Lazarides, MD, discusses the need for better drug discovery models in osteosarcoma and provides insight into a new personalized medicine pipeline that has the potential to redefine drug development in the field.

R. Lor Randall, MD, FACS, highlights the specific challenges faced by adolescent and young adult patients with sarcomas, the importance of promoting awareness of this issue, and the resources available to improve outcomes in this population.

Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field.

R. Lor Randall, MD, FACS, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.

William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.

Pathological fractures in adult patients with high-grade osteosarcoma of the extremities potentially correlates with inferior overall survival.

Joshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.

R. Lor Randall, MD, discusses the referral challenges for orthopedic oncologists and the importance of improving quality of life for patients with metastatic bone disease.

Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.

C. Parker Gibbs, MD, discusses the research behind p16 and p21 as predictive biomarkers for treatment response in patients with osteosarcoma.

The FDA has granted an accelerated approval to tazemetostat for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.

The FDA has granted a Regenerative Medicine Advanced Therapy designation to ADP-A2M4 (MAGE-A4) as a treatment for patients with synovial sarcoma.

The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma.

Brian A. Van Tine, MD, PhD, discusses the results of a phase I study looking at the effects of ADP-A2M4 in patients with synovial sarcoma.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of approving tazemetostat tablets as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.

The FDA has scheduled an Oncology Drugs Advisory Committee hearing for December 18, 2019, to discuss data supporting a new drug application for tazemetostat as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.

Ibrahim S. Alshaygy, MD, MSC, discusses research suggesting a smaller surgical resection margin for dermatofibrosarcoma protuberans.

Joshua M. Lawrenz, MD, discusses the use of hypofractionated radiotherapy versus conventional radiotherapy in soft tissue sarcoma.